secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001600620-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive
-------------------------------------------------------------------------------

- Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.
- Restructuring completed with $50-55M annual cost savings; headcount reduced ~25%.
- Company expects to be cash flow positive (ex buybacks) in Q2 2024, ahead of prior guidance.
- Reaffirms FY2024 net product revenue guidance of $200-220M.
- FDA approved label update for LUPKYNIS removing one-year efficacy limitation; quarterly kidney assessment after year one.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/0001600620-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/auph-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer